Abstract: A substance that can be a substitute for amylospheroids (ASPD) and a method for analyzing ASPD are provided. Viewed from one aspect, the present disclosure relates to a substance in which amyloid-? protein (A?) is cross-linked with a cross-linking agent that has a spacer arm length of between 4 ? and 50 ? inclusive or a cross-linking agent that has, as a spacer arm, not less than 1 and not more than 13 groups that are an oxyethylene group(s) (—CH2CH2O—) and/or an oxypropylene group(s) (—CH2CH2CH3O—). Viewed from another aspect, the present disclosure relates to a method for analyzing ASPD using the substance as a reference material.

Abstract: An object of the invention is to provide a method for assisting diagnosis of Alzheimer's disease (AD), and a detection reagent, a diagnosis kit and a diagnosis system for use in the method. Provided is a method for assisting diagnosis of AD, comprising the steps of: measuring an amount of a urine biomarker in a urine sample derived from urine collected from a subject; and determining whether the subject suffers from AD or has a high risk of developing AD based on the amount of the urine biomarker measured, wherein the urine biomarker is at least one urine protein selected from the group consisting of ApoA-I, ApoA-II, ApoA-IV, ApoB-100, ApoB-48, ApoC-I, ApoC-II, ApoC-III, ApoD, ApoE, IFITM1, IFITM2, IFITM3, NPC1, NPC2, NPC1L1, and MT.

Abstract: Provided are a procedurally simple and safe method and kit for measuring the concentration in a biological sample of a physiologically active substance which binds to a receptor that causes a change in intracellular cAMP concentration. By providing a composition including genetically-modified cells which show co-expression of a receptor that causes a change in intracellular cAMP concentration, a cyclic nucleotide-responsive calcium channel, and aequorin luminescent protein, it is possible to measure how much of a physiologically active substance which binds to said receptor is included in a biological sample.

Abstract: Provided are a procedurally simple and safe method and kit for measuring the concentration in a biological sample of a physiologically active substance which binds to a receptor that causes a change in intracellular cAMP concentration. By providing a composition including genetically-modified cells which show co-expression of a receptor that causes a change in intracellular cAMP concentration, a cyclic nucleotide-responsive calcium channel, and aequorin luminescent protein, it is possible to measure how much of a physiologically active substance which binds to said receptor is included in a biological sample.

Abstract: The present invention has an object to provide a novel therapeutic agent for hypercalcemia and bone diseases, and a novel compound capable of being used as an active ingredient of the therapeutic agent. The present invention is a therapeutic agent for hypercalcemia or bone diseases, comprising as an active ingredient a reveromycin A derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof. (R represents a hydroxyl-protecting group releasable under acidic conditions.